Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC011119 | Panoply™ Human ORAI1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC011119 | Panoply™ Human ORAI1 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD11621Z | Human ORAI1 adenoviral particles | Inquiry |
| LV20679L | human ORAI1 (NM_032790) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH368352 | shRNA set against Mouse ORAI1 (NM_175423.3) | Inquiry |
| SHH368348 | shRNA set against Human ORAI1 (NM_032790.3) | Inquiry |
| SHH368356 | shRNA set against Rat ORAI1 (NM_001013982.1) | Inquiry |
| SHR059856 | shRNA set against Rat Olr184_predicted(NM_001000182.1) | Inquiry |
| SHR080286 | shRNA set against Mouse Tmem142a(NM_175423.3) | Inquiry |
| SHW001306 | shRNA set against Chicken ORAI1 (NM_001030658) | Inquiry |
| SHW017524 | shRNA set against Danio rerio ORAI1B (NM_205600) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFL009736 | Mouse Orai1 cDNA Clone(NM_175423.3) | Inquiry |
| CDFR003058 | Rat Orai1 cDNA Clone(NM_001013982.1) | Inquiry |
| MiUTR1M-11859 | ORAI1 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-06816 | ORAI1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-11121 | ORAI1 miRNA 3'UTR clone | Inquiry |
| CDCB160200 | Human ORAI1 ORF clone (BC015369) | Inquiry |
| CDCB162781 | Chicken ORAI1 ORF Clone (NM_001030658) | Inquiry |
| CDCB178999 | Danio rerio ORAI1B ORF Clone (NM_205600) | Inquiry |
| CDCB188250 | Rabbit ORAI1 ORF clone (XM_002719735.2) | Inquiry |
| CDCL144685 | Mouse Orai1 ORF clone (NM_175423.3) | Inquiry |
| CDCR370135 | Rat Orai1 ORF Clone(NM_001013982.1) | Inquiry |
| CDCS416367 | Human ORAI1 ORF Clone (BC015369) | Inquiry |
| CDCS416368 | Human ORAI1 ORF Clone (BC013386) | Inquiry |
The ORAI1 gene is located on human chromosome 12q24.31 and encodes a critical pore-forming subunit of the calcium release-activated calcium (CRAC) channel, a landmark discovery in cellular signal transduction. ORAI1 is a four-pass transmembrane protein with both N- and C-termini in the cytoplasm, assembling at the plasma membrane to form a selective calcium-conducting channel. Its discovery emerged from studies of immunodeficiency and the molecular basis of store-operated calcium entry (SOCE). ORAI1 forms the channel pore of CRAC, and its activity is strictly dependent on the endoplasmic reticulum (ER) calcium sensor STIM1. In resting cells, STIM1 remains inactive; upon ER calcium depletion, STIM1 oligomerizes and relocates near the plasma membrane, where it directly activates ORAI1, allowing extracellular calcium influx. This process, known as store-operated calcium entry, is the primary source of cytosolic calcium signals in many cell types.
ORAI1-mediated SOCE is a highly conserved and fundamental mechanism for intracellular calcium signaling. Its role is especially critical in the immune system, notably in T lymphocyte activation and function. Upon T cell receptor recognition of antigens, intracellular calcium stores are released, STIM1 senses the depletion, and ORAI1 channels are activated to permit sustained calcium influx. This sustained calcium signal activates calmodulin and downstream effectors such as the phosphatase calcineurin, leading to NFAT dephosphorylation and nuclear translocation. NFAT then drives transcription of key effector genes, including interleukin-2 and interferon-γ, supporting T cell proliferation, differentiation, and immune memory formation. Thus, ORAI1 forms a central link between antigen recognition and gene expression programs in T cells.
Figure 1. Schematic representation of ORAI1-mediated SOCE in VSMC. (Shawer H, et al., 2021)
Beyond CRAC channels, ORAI1 can form arachidonic acid–regulated calcium (ARC) channels with other subunits, representing a store-independent calcium influx pathway that fine-tunes calcium signaling in specific physiological contexts. ORAI1 also functions in mast cells, B cells, skeletal muscle, neurons, and secretory epithelial cells-for example, mediating calcium transport in mammary epithelial cells critical for milk secretion.
The clinical significance of ORAI1 was first demonstrated through human severe combined immunodeficiency (SCID) caused by ORAI1 loss-of-function mutations. These autosomal recessive mutations result in profound T cell functional defects, recurrent life-threatening infections from early childhood, autoimmunity, and non-immune abnormalities, establishing ORAI1 as indispensable for human immune system development and function.
Given its central role in T cell activation, ORAI1 is an attractive target for novel immunosuppressive therapies for autoimmune diseases and transplant rejection. Selective blockade of ORAI1 via small molecules or monoclonal antibodies can inhibit pathological T cell activation without the broad cytotoxicity associated with calcineurin inhibitors. Several pharmaceutical companies and research institutions are developing ORAI1-specific inhibitors, which have shown efficacy in animal models of autoimmune diseases such as psoriasis and rheumatoid arthritis, and some lead compounds have entered early clinical trials.
Challenges remain in balancing immune suppression with potential side effects due to ORAI1's roles in calcium signaling in skeletal muscle and the nervous system. In oncology, modulating calcium signals in the tumor microenvironment may influence tumor survival and immune cell infiltration, though translational applications are still in early exploration. Overall, ORAI1 exemplifies a discovery rapidly advancing from fundamental science to clinical validation, offering promising avenues for therapeutic intervention in autoimmune diseases.
References